Lipomed

Merrimack Pharmaceuticals is a privately held integrated biotechnology company. The company is dedicated to the discovery and development of therapies for the treatment of autoimmune disease and cancer. Its goal is to provide patients and physicians with some of the best possible treatments and support its pharmaceuticals with the tools to enable the prescription of the right drug for the right patient. The company is advancing a pipeline of clinical and early-stage biologics that represent patient-directed, targeted therapies. Its discovery and development efforts are founded on its proprietary Network Biology research engine. Its lead product, MM-093, is in clinical trials for the treatment of patients with rheumatoid arthritis and psoriasis. Merrimack Pharmaceuticals is based in Cambridge, Mass.

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.